Details of the Drug Reposition

General Information of This Drug (ID: DMQ8FR2)

• Drug Name: Prednisolone (DMQ8FR2)
• Synonyms: Nanocort; Prednisolone (injectable liposome formulation, rheumatoid arthritis); Prednisolone (injectable liposome formulation, rheumatoid arthritis), Enceladus; Prednisolone (injectable liposome formulation, rheumatoid arthritis), Galapagos
• Therapeutic Class: Anticancer Agents
• Drug Type: Small molecular drug

Information on Drug Reposition of This Drug

48 Approved Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Sympathetic ophthalmia	DISD35KW	N.A.	Approved	[1]
Serum sickness	DIS0MRKJ	N.A.	Approved	[1]
Rheumatic heart disease	DISCI8JQ	N.A.	Approved	[1]
Primary cutaneous T-cell lymphoma	DIS35WVW	N.A.	Approved	[1]
Polymyalgia rheumatica	DIS5F36E	N.A.	Approved	[1]
Miliary tuberculosis	DIS4AT5W	N.A.	Approved	[1]
Microscopic polyangiitis	DIS74KSO	N.A.	Approved	[1]
Leukemia	DISNAKFL	N.A.	Approved	[1]
Keratitis	DISMFOEI	N.A.	Approved	[1]
Hypersensitivity pneumonitis	DIS5IW5K	N.A.	Approved	[1]
Granuloma annulare	DISMOUMI	N.A.	Approved	[1]
Exanthem	DISAFOQN	N.A.	Approved	[1]
Erythema multiforme	DISKCLM1	N.A.	Approved	[1]
Epicondylitis	DIS0R2VM	N.A.	Approved	[1]
Disorder of orbital region	DISH0ECJ	N.A.	Approved	[1]
Diamond-Blackfan anemia	DISI2SNW	N.A.	Approved	[1]
Dacryocystitis	DISFBZLV	N.A.	Approved	[1]
Chronic graft versus host disease	DIS1MM9J	N.A.	Approved	[1]
Bursitis	DISCF7Y9	N.A.	Approved	[1]
Blepharoconjunctivitis	DIS4PG4J	N.A.	Approved	[1]
Aspiration pneumonitis	DIS5S4DE	N.A.	Approved	[1]
Acute adrenal insufficiency	DIS66YLV	N.A.	Approved	[1]
Demodex blepharitis	DISDSJDZ	1G07	Approved	[1]
Malignant solid tumour	DISITUVU	2C10-2F32	Approved	[2]
Myeloproliferative neoplasm	DIS5KAPA	2A20	Approved	[1]
Mycosis fungoides	DIS62RB8	2B01	Approved	[1]
Autoimmune haemolytic anaemia	DIS7MS3M	3A20	Approved	[1]
Angioedema	DIS90QDN	4A00.15	Approved	[1]
Systemic lupus erythematosus	DISI1SZ7	4A40.0	Approved	[1]
Sarcoidosis	DISE5B8Z	4B20.5	Approved	[1]
Congenital adrenal hyperplasia	DISG873W	5A71.01	Approved	[1]
Addison disease	DIS7HNOH	5A74.0	Approved	[1]
Cerebral edema	DIS4GHSB	8D60.1	Approved	[1]
Corneal ulcer	DIS8YN8N	9A76	Approved	[1]
Allergic rhinitis	DIS3U9HN	CA08.0	Approved	[1]
Severe asthma	DISAVQI3	CA23	Approved	[1]
Pneumocystis pneumonia	DISFSOM3	CA40.20	Approved	[1]
Ischemia-reperfusion injury	DISG8CCO	DB98.B	Approved	[1]
Crohn disease	DIS2C5Q8	DD70	Approved	[1]
Ulcerative colitis	DIS8K27O	DD71	Approved	[1]
Inflammatory bowel disease	DISGN23E	DD72	Approved	[1]
Skin disease	DISDW8R6	EA00-EM0Z	Approved	[1]
Psoriasis	DIS59VMN	EA90	Approved	[1]
Dermatitis herpetiformis	DIS0TC0G	EB44	Approved	[1]
Rosacea	DIS02PWG	ED90.0	Approved	[1]
Psoriatic arthritis	DISLWTG2	FA21	Approved	[1]
Fever	DISJGEAQ	MG26	Approved	[1]
Corneal abrasion	DIS3SD7J	NA06.4	Approved	[1]

1 Phase 3 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Multiple sclerosis	DISB2WZI	8A40	Phase 3	[3]

3 Withdrawn Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Pemphigus	DISZAZ6M	N.A.	Withdrawn	[4]
Stevens-Johnson syndrome	DISZG4YX	N.A.	Withdrawn	[5]
Allergic conjunctivitis	DISZ5ZJN	9A60.02	Withdrawn	[6]

5 Discontinued in Phase 3 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Humoral hypercalcemia of malignancy	DISQQ62D	N.A.	Discontinued in Phase 3	[7]
Eosinophilic pneumonia	DISTRF6P	N.A.	Discontinued in Phase 3	[8]
Anterior uveitis	DISQ7EAD	9A96	Discontinued in Phase 3	[9]
Atopic dermatitis	DISTCP41	EA80	Discontinued in Phase 3	[10]
Seborrhoeic dermatitis	DISNWVJU	EA81	Discontinued in Phase 3	[11]

12 Discontinued in Phase 2 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Exfoliative dermatitis	DISQEWIW	N.A.	Discontinued in Phase 2	[12]
Iritis	DISSA7AC	N.A.	Discontinued in Phase 2	[13]
Tendinitis	DISS7ANY	N.A.	Discontinued in Phase 2	[14]
Bacterial conjunctivitis	DIST79FU	N.A.	Discontinued in Phase 2	[15]
Thyroiditis	DISTCV24	N.A.	Discontinued in Phase 2	[16]
Non-hodgkin lymphoma	DISS2Y8A	2B33.5	Discontinued in Phase 2	[17]
Giant cell arteritis	DISSP87T	4A44.2	Discontinued in Phase 2	[18]
Glomerulonephritis	DISPZIQ3	5D00.Y	Discontinued in Phase 2	[19]
Pulmonary fibrosis	DISQKVLA	CB03.4	Discontinued in Phase 2	[20]
Musculoskeletal disorder	DISPPN0O	FA00-FC0Z	Discontinued in Phase 2	[21]
Rheumatoid arthritis	DISTSB4J	FA20	Discontinued in Phase 2	[22]
Ankylosing spondylitis	DISRC6IR	FA92.0	Discontinued in Phase 2	[23]

4 Discontinued in Phase 1 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Tenosynovitis	DISR5H9R	N.A.	Discontinued in Phase 1	[24]
Nephrotic syndrome	DISSPSC2	N.A.	Discontinued in Phase 1	[25]
Autoimmune disease	DISORMTM	4A40-4A45	Discontinued in Phase 1	[26]
Contact dermatitis	DISQ3AU0	EK0Z	Discontinued in Phase 1	[27]

7 Investigative Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Synovitis	DISW2GPY	N.A.	Investigative	[1]
Iridocyclitis	DISV6UP4	N.A.	Investigative	[1]
Classic Hodgkin lymphoma	DISV1LU6	N.A.	Investigative	[1]
Beta-thalassemia major	DISW06BV	N.A.	Investigative	[1]
Acquired thrombocytopenia	DISXH01C	N.A.	Investigative	[1]
Follicular lymphoma	DISVEUR6	2A80	Investigative	[1]
Sjogren syndrome	DISUBX7H	4A43.20	Investigative	[1]

References

• [1] Prednisolone FDA Label
• [2] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [3] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2866).
• [4] Escitalopram in Anxiety Associated Chronic Obstructive Pulmonary Disease (COPD) Exacerbations
• [5] Mifepristone in Children With Refractory Cushing's Disease
• [6] A Trial of Glutamine to Prevent Oxaliplatin Neurotoxicity and a Pharmacokinetic Analysis of Oxaliplatin
• [7] Low-Dose Hormone Replacement Therapy and Alendronate for Osteoporosis
• [8] Escitalopram in Treating Depression in Patients With Advanced Lung or Gastrointestinal Cancer
• [9] A Study to Compare the Efficacy and Safety of Tacrolimus Capsules With Leflunomide Tablets in Lupus Nephritis Patients
• [10] Autologous Stem Cell Rescue With CD133+ Selected Cells in High-Risk Neuroblastoma
• [11] Combination Chemotherapy, Surgery, and Radiation Therapy With or Without Dexrazoxane and Trastuzumab in Treating Women With Stage III or Stage IV Breast Cancer
• [12] Safety/Efficacy Study of SGN-15 (Antibody-Drug Conjugate) Combined With Gemcitabine in Patients With Ovarian Cancer
• [13] A Phase II Study of Pemetrexed and Carboplatin in the Treatment of Esophageal Cancer
• [14] A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors
• [15] Study of Sildenafil to Treat Newborns With Persistent Pulmonary Hypertension
• [16] A Study to Assess the Safety and Efficacy of 7 Days Treatment With a Novel Analgesic in Subjects With Peripheral Neuropathic Pain
• [17] Peripheral Stem Cell Transplant in Treating Patients With High-Risk Leukemia
• [18] Tezacitabine and Oxaliplatin for the Treatment of Patients With Metastatic Colorectal Cancer
• [19] Kava Kava for the Treatment of Generalized Anxiety Disorder (GAD)
• [20] Study to Evaluate the Efficacy and Safety of Lenalidomide in the Treatment of Complex Regional Pain Syndrome Type 1
• [21] Radiolabeled Monoclonal Antibody Plus Rituximab With and Without Filgrastim and Interleukin-11 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
• [22] Sildenafil Citrate for the Treatment of Established Pre-Eclampsia
• [23] A Study to Test a Measure of Symptoms of Older Men With Low Testosterone On and Off Testosterone Replacement Treatment (P05815)
• [24] ClinicalTrials.gov (NCT01403285) Peptide-based Glioma Vaccine IMA950 in Patients With Glioblastoma. U.S. National Institutes of Health.
• [25] Sirolimus for Eosinophil-Associated Gastrointestinal Disorders
• [26] An Open-Labeled Pilot Study of Biomarker Response Following Short-Term Exposure to Metformin
• [27] A Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Pediatric Participants With Advanced Solid Tumors (P05883, MK-7454-006)